# JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

> **NCT06678282** · NA · RECRUITING · sponsor: **Shenzhen Genocury Biotech Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- B-NHL
- B-ALL

## Interventions

- **DRUG:** JY231 Injection

## Key facts

- **NCT ID:** NCT06678282
- **Lead sponsor:** Shenzhen Genocury Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-07
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06678282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06678282, "JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06678282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*